drugset / Trial / NCT02403284

The Effect of Liraglutide on Dietary Lipid Induced Insulin Resistance in Humans

NCT02403284

RandomizedCrossoverQuadruple-blindBasic science

Summary

In this research study, investigators will test the effects of an approved medication for diabetes,Liraglutide, to reduce insulin resistance that develops from eating a diet high in saturated fats.

Timeline

Start
2013-03
Primary completion
2021-04-28
Completion
2023-11-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Liraglutide Peptide 1.8 mg Subcutaneous

Indications

No indication recorded.